Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

Novo Holdings will sell three of Catalent's fill-finish sites - in Italy, Belgium and the United States - onto Novo Nordisk for $11 billion. The sites will then by fully used by Novo Nordisk for ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

Another source said Catalent is preparing senior management for the deal to go through. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab ...